LeMaitre Vascular, Inc. (LMAT): Price and Financial Metrics
LeMaitre Vascular, Inc. (LMAT)
Today's Latest Price: $37.49 USD
Updated Dec 1 4:00pm
Add LMAT to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 143 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
LMAT Stock Summary
- With a one year PEG ratio of 1,686.65, Lemaitre Vascular Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 97.63% of US stocks.
- Price to trailing twelve month operating cash flow for LMAT is currently 30.53, higher than 86.11% of US stocks with positive operating cash flow.
- With a year-over-year growth in debt of 1,091.05%, Lemaitre Vascular Inc's debt growth rate surpasses 98.18% of about US stocks.
- Stocks that are quantitatively similar to LMAT, based on their financial statements, market capitalization, and price volatility, are SSD, SSTK, ATRI, PLPC, and CRTO.
- LMAT's SEC filings can be seen here. And to visit Lemaitre Vascular Inc's official web site, go to www.lemaitre.com.
LMAT Stock Price Chart Interactive Chart >
LMAT Price/Volume Stats
| Current price | $37.49 | 52-week high | $41.86 |
| Prev. close | $39.39 | 52-week low | $18.76 |
| Day low | $37.10 | Volume | 163,100 |
| Day high | $39.80 | Avg. volume | 131,888 |
| 50-day MA | $34.72 | Dividend yield | 0.96% |
| 200-day MA | $29.32 | Market Cap | 762.62M |
LeMaitre Vascular, Inc. (LMAT) Company Bio
LeMaitre Vascular is a provider of devices and implants for the treatment of peripheral vascular disease. The company was founded in 1983 and is based in Burlington, Massachusetts.
LMAT Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $37.49 | $46.93 | 19% |
We started the process of determining a valid price forecast for Lemaitre Vascular Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Lemaitre Vascular Inc ranked in the 51th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 19.67% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Lemaitre Vascular Inc, consider:
- The business' balance sheet reveals debt to be 9% of the company's capital (with equity being the remaining amount). Approximately merely 22.32% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than just 0% of stocks in its sector (Healthcare).
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 17% |
| 1% | 18% |
| 2% | 19% |
| 3% | 20% |
| 4% | 21% |
| 5% | 23% |
Want more companies with a valuation profile/forecast similar to that of Lemaitre Vascular Inc? See EGRX, SNY, AMED, FONR, and CBPO.
Loading social stream, please wait...